



SAFE HARBOUR

This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of IDT Australia Ltd to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the action of commercial partners, the timing and effects of regulatory actions, the strength of competition and the effectiveness of the Company's commercial strategy.

IDT AUSTRALIA LTD INVESTMENT PROPOSITION

The Business

- ◉ Portfolio of 23 US FDA approved generic drugs
- ◉ Contract drug development
- ◉ Contract drug manufacturing
- ◉ Drug development services incl. clinical trials

High tech 12,000m² facility in Boronia VIC. Replacement value ~\$75m

Low capacity utilisation. As generic drug manufacture ramps up, expect extreme operational leverage with rapid expansion of volumes & margins

Further pipeline expansion planned

IDT: We make good medicine.



www.idtaus.com.au

◀ 3 ▶

30 YEAR HISTORY A PLATFORM FOR RAPID GROWTH

IDT Organic Base Business:
Provides revenues and capabilities

Drug development
services



Contract drug
manufacture



Contract clinical services



Transformative
M&A



IDT Generics:
Leverages facilities and
multiplies margins

Proprietary IDT Generic
Drug Portfolio



www.idtaus.com.au

◀ 4 ▶

IDT PORTFOLIO GROWTH 23 US GENERIC DRUGS

- Purchased Nov2014, now being moved into IDT facility and first batches manufactured
- Therapeutic areas incl.
 - Neurology
 - Infectious diseases
 - Cardiovascular
 - Respiratory
- Addressable market of \$US460m (IMS*)
- Rapid path to revenues (12-18 months) for initial cohort of products
- Minimal CAPEX



* Independent industry sales data



www.idtaus.com.au

< 5 >

NEW PRODUCTS

Product	Dose Form	Indication	Class
Aminophylline	Tablet	Asthma	Respiratory
Carbidopa & Levodopa	Tablet	Parkinson's Disease	Neurology
Ciprofloxacin	Tablet	Bacterial Infections	Infectious Disease
Clarithromycin	ER Tablet	Bacterial Infections	Infectious Disease
Dexamethasone	Tablet	Anti-Inflammatory	Steroid
Diflunisal	Tablet	Osteoarthritis	NSAID
Dipyridamole	Tablet	Post Surgical Clots	Cardiovascular
Doxazosin	Tablet	Prostatic Hyperplasia	Urology
Etodolac	Capsule	Rheumatoid Arthritis	Immune
Etodolac ER	ER Tablet	Rheumatoid Arthritis	Immune



www.idtaus.com.au

< 6 >

NEW PRODUCTS cont.

Product	Dose Form	Indication	Class
Flecainide	Tablet	Tachycardia	Cardiovascular
Fluconazole	Tablet	Infectious Disease	Infectious Disease
Leucovorin	Tablet	Methotrexate Antidote	Oncology
Methoxsalen	Capsule	Vitilago	Dermatology
Mexiletine	Capsule	Arrhythmia	Cardiovascular
Nefazodone	Tablet	Depression	Neurology
Nortriptyline	Capsule	Depression	Neurology
Pindolol	Tablet	Hypertension	Cardiovascular
Prazosin	Capsule	Hypertension	Cardiovascular
Procainamide	Capsule	Arrhythmia	Cardiovascular
Procainamide ER	ER Tablet	Arrhythmia	Cardiovascular
Tetracycline	Capsule	Bacterial Infections	Infectious Disease



www.idtaus.com.au

< 7 >

US MARKET RE-ENTRY PROCESS, FIRST PRODUCTS

- Product dossiers transferred to IDT ► Tech transfer ► Manufacturing methods to IDT ► Manufacture of stability batches ► FDA notified
- Subsequent products may require prior approval process, taking approximately 6 months from FDA submission
- Products all long genericized with established markets
 - predictable volumes & pricing, little risk of new competitors
- Initial revenues could be realised H2 FY15/16
- Gross margin shared with marketing/distribution partner
- Assumed conservative market share & modest discount to existing market prices to assist entry
- Peak revenues attainable 3 years from launch & sustainable
- In late stage discussions with multiple potential distribution partners



www.idtaus.com.au

< 8 >

PATH TO MARKET

IDT US DISTRIBUTOR APPOINTMENTS

- Temozolomide distribution secured in the US, equitable gross margin split (US\$300 US addressable market)
- US distributor for purchased ANDA products:
 - Strong competition for the assets, 12 distribution term sheets received
 - Strong potential partners
 - Generous terms with near term revenues
 - Moving closer to finalizing appointment


www.idtaus.com.au


VALUE CREATION


IDT OPERATIONAL PROGRAMS

- ANDAs; first batches of Doxazosin (US\$65m US sales) manufactured, second product in preparation
- Temozolomide ANDA filed with US FDA Nov 2013
 - Mayne distribution
 - Launch due 2016/2017
- Project Teton (US\$80m global sales)
 - Feasibility studies for manufacture complete
 - Manufacturing partner selection ongoing
 - Targeting far greater value share from FY17/18


www.idtaus.com.au


EFFECT OF OPERATIONAL LEVERAGE

SCENARIO: Organic growth + product registrations



idt
GOOD MEDICINE

www.idtaus.com.au

11

RECENT COMPARABLE TRANSACTIONS

- ANI Pharma purchase of 31 generic assets Nov 2013
 - Was toll manufacturer with underutilised assets, now a speciality generic pharma
 - Market cap \$60m to \$600m since transaction
- Mayne Pharma purchase of Forest Pharma assets Feb 2014
 - Expansion of existing specialty generic pharma strategy via acquisition

Transaction dates



idt
GOOD MEDICINE

www.idtaus.com.au

12

DEVELOPING OUR OWN SPECIALITY GENERICS



Example: PROJECT TETON:

- IDT currently the dominant supplier of active pharmaceutical ingredients for a significant oncology product, yet capturing only **2% of the VALUE** as the API supplier.
- Registration and supply of injectable **Finished Dose Form** could increase IDT's share of the gross profit to **50-60%**



www.idtaus.com.au

◀ 13 ▶



WHO WE MANUFACTURE FOR

OUR CUSTOMERS ARE WORLD LEADERS



www.idtaus.com.au

< 15 >

CREATING WORLD LEADING PRODUCTS



SENSITIZING DRUGS



ANTI-CANCER DRUGS



HORMONES



CARBOHYDRATE DRUGS



HIGH CONTAINMENT TABS/CAPS



HIGH CONTAINMENT TAB COATING



www.idtaus.com.au

< 16 >

MEDICINES MADE IN OUR MELBOURNE FACILITY



- ⦿ \$75m advanced manufacturing facility
- ⦿ 12,000m² state-of-the-art
- ⦿ Current 10-15% capacity utilisation
- ⦿ Large scope for growth without need for material increases in:
 - ↗ CAPEX, or
 - ↗ site support costs

Ability to manufacture from gram to tonnage scale + advanced tableting & capsuling capabilities

Low capacity utilisation & high fixed costs deliver extreme **operational leverage**



www.idtaus.com.au

◀ 17 ▶

TRIALED IN OUR CLINICAL UNIT

- ⦿ **CMAX** clinical trials facility
- ⦿ **Established** 1993
- ⦿ **Australia's** oldest, largest, most experienced clinical trials unit
- ⦿ **50** bed clinical unit located at Royal Adelaide Hospital
- ⦿ **Uses** services of RAH – Ethics Committee, medical specialists & services
- ⦿ **FDA** inspected
- ⦿ **Delivered** 500+ clinical trial programs for 60+ pharma & biotech companies from 21+ countries




www.idtaus.com.au

◀ 18 ▶



A PRESCRIPTION FOR GROWTH



GOOD MEDICINE & HIGHER RETURNS FOR IDT



SELL MORE EXISTING PRODUCTS

- High fixed costs = operational leverage.
- As a result, profits will rise faster than revenues past breakeven point.



EXTRACT MORE PROFITS

- Extract more profits from those products to improve our share of the value chain.



DEVELOP & ACQUIRE MORE PRODUCTS

- Develop & acquire more products to leverage our facilities & capabilities.
- This growth will in turn finance further acquisitions.



NOV14 ACQUISITION

This transaction moves IDT rapidly towards profits:

- Purchased 23 approved generic drug products;
- Reduced regulatory lag to get to market vs in-house;
- Reduced technical development & spend in-house.



www.idtaus.com.au

◀ 21 ▶

HIGHLIGHTS OF THE PAST YEAR



ACQUISITION OF GENERIC US DRUG PORTFOLIO

Transformative step for the company, rapid return to profitability



BUILD IN-HOUSE DRUG PORTFOLIO

Filed first IDT ANDA for temozolomide
Temozolomide US distribution deal – milestones & profit split
Further projects in development



NEW MANAGEMENT TEAM

New management team and strengthen board



GROW EXISTING DRUG DEVELOPMENT SERVICES REVENUES

Significant increases in sales pipeline, manufacturing and clinical services
Beginning to see this flow through into significant revenue increases



CONTAINMENT OF COSTS

Head count, utilities, other overheads











www.idtaus.com.au

◀ 22 ▶

BOARD & MANAGEMENT IN PLACE TO DELIVER

MANAGEMENT TEAM

-  Dr Paul D R MacLeman (CEO & MD)
-  Deb Cailles (Market Access)
-  Jane Kelly (Clinical)
-  Joanna Johnson (CFO)
-  Stéphane Redey (Manufacturing)
-  Mark Rowlands (Bus Dev)
-  Dr David Sparling (Corp Dev)
-  Alf Staffa (Quality)

BOARD

-  Graeme Kaufman (Chairman)
-  Dr Paul D R MacLeman (MD)
-  Geoff Lord (Vice Chairman)
-  Dr Graeme Blackman (NED)
-  Reo Shigeno (NED)



www.idtaus.com.au

◀ 23 ▶

FINANCIALLY POSITIONED TO DELIVER

FINANCIALS

	2013	2014
REVENUE	\$13.4m	\$13.4m
EBIT*	(\$4.4m)	(\$6.0m)
CASH BALANCE	\$0.6m	\$2.4m
DEBT**	\$1.9m	\$0.1m




*After one-off charges

** \$3m unused debt facility available

MARKET CAP \$47.8m (01Jun15)



CAPITAL STRUCTURE





 SHARES ON ISSUE	191.1M
 UNLISTED OPTIONS	500,000
 TOP 20 SHAREHOLDERS	60.5%



www.idtaus.com.au

◀ 24 ▶

TARGET 2015 MILESTONES


-  INCREASED 2014/15 ORGANIC SALES GROWTH
-  MOVEMENT OF AN ADDITIONAL INTERNAL PRODUCT TOWARDS MARKET
-  PROGRESS WITH RE-COMMERCIALISATION OF 23 ACQUIRED US PRODUCTS
-  MOVE FROM SERVICE PROVIDER, TOWARDS SPECIALTY GENERIC PHARMACEUTICAL COMPANY, GROWTH & PROFITS



www.idtaus.com.au

< 25 >

CONTACT US



Dr Paul D R MacLeman
MANAGING DIRECTOR

 +61 (0) 3 9801 8888
info@idtaus.com.au
www.idtaus.com.au

Follow Us on Twitter @IDTAus



www.idtaus.com.au

< 26 >

